Quaternary cytoreductive surgery in ovarian cancer: Does surgical effort still matter

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 32-38

  Fotopoulou, C ^a   Savvatis, K ^a   Kosian, P ^a   Braicu, I E ^a   Papanikolaou, G ^a   Pietzner, K ^a   Schmidt, S C ^a   Sehouli, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

morbidity; Ovarian cancer relapse; overall survival; quaternary cytoreduction; tumour dissemination

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMEN; ADULT; AGED; ANASTOMOTIC INSUFFICIENCY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTESTINE OBSTRUCTION; MORBIDITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE FISTULA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RELAPSE; SEPSIS; SHORT BOWEL SYNDROME; SURGICAL MORTALITY; SURVIVAL RATE; THROMBOEMBOLISM;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RECURRENCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84872525006     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.544     Document Type: Article

References (36)

1. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO, Podratz KC, Cliby WA (2009) Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg 208(4): 614-620.
2. Benedetti P, De Vivo A, Bellati F, Manci N, Perniola G, Basile S, Muzii L, Angioli R (2007) Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 14(3): 1136-1142.
3. Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C (2012) Primary vs secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumor pattern and surgical outcome. Eur J Cancer 48(5): 687-694.
4. Bristow RE (2000) Surgical standards in the management of ovarian cancer. Curr Opin Oncol 12(5): 474-480.
5. Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR (2004) Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94(3): 650-654.
6. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106(9): 1933-1939.
7. Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR (2004) Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94: 650-654.
8. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U. Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC (2005) 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16(Suppl 8): viii7-viii12.
9. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115(6): 1234-1244.
10. Fanfani F, Fagotti A, Gallotta V, Ercoli A, Pacelli F, Costantini B, Vizzielli G, Margariti PA, Garganese G, Scambia G (2010) Upper abdominal surgery in advanced and recurrent ovarian cancer: role of diaphragmatic surgery. Gynecol Oncol 116(3): 497-501.
11. Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J (2011a) Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol 18: 49-57.
12. Fotopoulou C, Rolf Richter R, Elena-Ioana Braicu E-I, Kuhberg M, Feldheiser A, Schefold JC, Lichtenegger W, Sehouli J (2011b) Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking. Ann Surg Oncol 18(9): 2629-2637.
13. Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Jalid S (2012) Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol; e-pub ahead of print September 2012.
14. Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A (2000) Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 79: 344-349.
15. Gultekin M, Velipaşaoǧlu M, Aksan G, Dursun P, Dogan NU, Yuce K, Ayhan A (2008) A third evaluation of tertiary cytoreduction. J Surg Oncol 98(7): 530-534.
16. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J (2006) Surgery in recurrent ovarian cancer: the AGO DESKTOP Ovar trial. Ann Surg Oncol 13(12): 1702-1710.
17. Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, du Bois A (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16(5): 1324-1330.
18. Hizli D, Boran N, Yilmaz S, Turan T, Altinbaş SK, Celik B, Köse MF (2012) Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 163(1): 71-75.
19. International Federation of Gynecology and Obstetrics: Changing in definitions of clinical staging for carcinoma of the cervix and ovary (1987) Am J Obstet Gynecol 156: 263-264.
20. Karam AK, Santillan A, Bristow RE, Giuntoli 2nd R, Gardner GJ, Cass I, Karlan BY, Li AJ (2007) Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol 104(2): 377-380.
21. Kurman RJ, Shih IeM (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27(2): 151-160.
22. Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3): 433-443.
23. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198(4): 351-356.
24. Leitao Jr MM, Kardos S, Barakat RR, Chi DS (2004) Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol 95: 181-188.
25. Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Bois A. AGO Ovarian Committee; AGO Ovarian Cancer Study Group (AGO-OVAR) (2005) The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer 15(Suppl 3): 195-198.
26. Schorge JO, Wingo SN, Bhore R, Heffernan TP, Lea JS (2010) Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet 108(2): 123-127.
27. Sehouli J, Könsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, Lichtenegger W (2003) 'IMO'-intraoperative mapping of ovarian cancer. Zentralbl Gynakol 125(3-4): 129-135.
28. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, Gülten OO (2009) Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 99(7): 424-427.
29. Shih IeM, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11(20): 7273-7279.
30. Shih IeM, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5): 1511-1518.
31. Shih KK, Chi DS, Barakat RR, Leitao Jr MM (2010a) Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol 117: 330-335.
32. Shih KK, Chi DS, Barakat RR, Leitao Jr MM (2010b) Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 116(3): 364-369.
33. Singer G, Kurman RJ, Chang H-W, Cho SKR, Shih I-M (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160: 1223-1228.
34. Vang R, IeM Shih, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16(5): 267-282.
35. Wimberger P, Wehling M, Lehmann M, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A (2010) Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. An exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 17: 1642-1648.
36. Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS (2008) The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 108(2): 287-292.